Health Canada approves MYQORZO for treating symptomatic obstructive hypertrophic cardiomyopathy in adults.

Health Canada has approved MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as NYHA class II-III. MYQORZO is an oral drug that reduces heart muscle contractility and obstruction, improving exercise capacity and symptoms. This marks the fifth regulatory approval for MYQORZO globally, following approvals in the US, China, EU, and UK. The approval is based on positive Phase 3 trial results showing significant benefits and a well-tolerated safety profile. Cytokinetics plans to expand access to MYQORZO and continue developing treatments for related heart conditions.

Cytokinetics Inc (CYTK) trades at USD 61.55 on Pluang as of Oct 19, 2026 18:43 WIB, down 0.65% in one day. The stock's market cap is $8.62 billion with a 52-week range between $54.76 and $87.26. Volume stands at 1,204,683 shares, reflecting steady investor interest amid the recent regulatory news.